Alterola Biotech, Inc. (ABTI)

Alterola Biotech Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Selling, General & Admin	2.49	2.08	1.85	6.13	0.31
Research & Development	0.06	0.03	0.18	0.34	-
Operating Expenses	2.55	2.11	2.03	6.47	0.31
Operating Income	-2.55	-2.11	-2.03	-6.47	-0.31
Currency Exchange Gain (Loss)	0.07	0.03	-0.02	-	-
Other Non Operating Income (Expenses)	-0.04	-0.04	-0.02	0	-
EBT Excluding Unusual Items	-2.86	-2.12	-2.07	-6.47	-0.31
Asset Writedown	-0.39	-0.39	-	-	-
Other Unusual Items	0.28	0.14	-	-	-
Pretax Income	-2.97	-2.37	-2.07	-6.47	-0.31
Net Income	-2.78	-2.37	-2.07	-6.47	-0.31
Net Income to Common	-2.78	-2.37	-2.07	-6.47	-0.31
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	1,375	1,052	807	770	-
Shares Outstanding (Diluted)	1,375	1,052	807	770	-
Shares Change	70.86%	30.31%	4.82%	-	-
EPS (Basic)	-0.00	-0.00	-0.00	-0.01	-
EPS (Diluted)	-0.00	-0.00	-0.00	-0.01	-
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
EBIT	-2.55	-2.11	-2.03	-6.47	-0.31

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2024

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error